Promacta
Term · Oncology and biomedicine · MLC-T-ONC-006960
A drug used to treat thrombocytopenia (a low blood platelet count) in adults and children with chronic immune thrombocytopenic purpura that did not get better with other treatment. Promacta is also used to treat severe aplastic anemia. It is also being studied in the treatment of other conditions and types of cancer. Promacta binds to the thrombopoietin receptor, which causes the bone marrow to make more platelets. It is a type of thrombopoietin receptor agonist. Also called eltrombopag olamine.
| Identifier | MLC-T-ONC-006960 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | eltrombopag olamine |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-006960",
"term": "Promacta",
"field": "Oncology and biomedicine",
"definition": "A drug used to treat thrombocytopenia (a low blood platelet count) in adults and children with chronic immune thrombocytopenic purpura that did not get better with other treatment. Promacta is also used to treat severe aplastic anemia. It is also being studied in the treatment of other conditions and types of cancer. Promacta binds to the thrombopoietin receptor, which causes the bone marrow to make more platelets. It is a type of thrombopoietin receptor agonist. Also called eltrombopag olamine.",
"synonyms": [
"eltrombopag olamine"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/promacta/"
}
Record 13,695 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.